|
|
|
| Application of Xueshuantong Capsule Combined with Conbercept in Patients with Central Retinal Vein Occlusion and Macular Oedema |
| TANG Huichao, LI Man, WANG Dongmei, et al |
| 363th Hospital, Sichuan Chengdu 610041, China |
|
|
|
|
Abstract Objective: To explore the application effect of Xueshuantong capsule combined with Conbercept in patients with central retinal vein occlusion (CRVO) and macular oedema. Methods: A total of 90 patients with ischemic CRVO and macular oedema were enrolled between October 2019 and September 2021. According to simple random grouping method, they were divided into group A (45 cases, 45 eyes, Conbercept combined with Xueshuantong capsules) and group B (45 cases, 45 eyes, Conbercept). All were treated for 3 months. The onset time of visual acuity, retinal circulation time, central macular thickness (CMT), fundus hemodynamics, best corrected visual acuity (BCVA), serum indexes and adverse reactions in the two groups were compared. Results: The response rate of treatment in the two groups was similar (χ2=0.179, P>0.05). Compared with group B, onset time of visual acuity was shorter in group A (t=2.237, P<0.05). After treatment, retinal circulation time was similar in the two groups (t=1.149, P>0.05). After 2 and 3 months of treatment, CMT was thinner in group A than group B (t=3.884, 2.104, P<0.05). Compared with group B after treatment, increments of peak systolic velocity and end-diastolic velocity were greater in group A, while decrements of resistance index and pulsatility index were greater in group A (t=7.240, 6.452, 6.202, 6.442, P<0.05). After 1 month of treatment, BCVA log MAR was lower in group A than group B (t=2.472, P<0.05). Compared with group B after treatment, increment of serum nitric oxide synthetase was greater in group A, while decrements of interleukin-6 and vascular endothelial growth factor were greater in group A (t=7.799, 15.034, 4.973, P<0.05). The incidence of adverse reactions was similar in the two groups (P>0.05). Conclusion: Compared with Conbercept alone, Conbercept combined with Xueshuantong capsule is conducive to the relief of macular edema, improvement of retinal microcirculation, and vision recovery in CRVO.
|
|
|
|
|
|
[1] Arrigo A,Knutsson KA,Rajabjan F,et al.Combined central retinal vein occlusion and branch retinal artery occlusion treated with intravitreal dexamethasone implant:a case report[J].Eur Ophthalmol,2021,31(2):74-76.
[2] Hwang BE,Kim M,Park YH.Role of the choroidal vascularity index in branch retinal vein occlusion (BRVO) with macular edema[J].PLoS One,2021,16(10):e0258728.
[3] 马骊珠,乔亚光.复方血栓通胶囊结合阿托伐他汀片对急性脑梗死神经功能和血脂指标的影响[J].中华中医药学刊,2022,40(2):227-230.
[4] 赵堪兴,杨培增.眼科学[M].北京:人民卫生出版社,2013.213-215.
[5] Raval V,Nayak S,Saldanha M,et al.Combined retinal vascular occlusion:demography,clinical features,visual outcome,systemic co-morbidities,and literature review[J].Indian Ophthalmol,2020,68(10):2136-2142.
[6] 凌佼佼,陆璐,杨芳,等.复方血栓通胶囊对眼压控制后青光眼患者眼血流动力学的影响[J].现代中西医结合杂志,2020,29(12):1331-1334.
[7] 王珏,杜玮,李燕.羟苯磺酸钙联合复方血栓通胶囊治疗老年糖尿病视网膜病变的疗效及对血液流变学的影响[J].中国老年学杂志,2020,40(8):1603-1606.
[8] 马宏杰,王家良.复方血栓通胶囊治疗视网膜静脉阻塞继发黄斑水肿及对眼血流动力学的影响[J].吉林中医药,2018,38(9):1042-1046.
[9] 孙岩,马健萍,徐茂生,等.复方血栓通滴丸治疗视网膜静脉阻塞的临床安全性与有效性观察[J].辽宁中医杂志,2020,47(3):133-136.
[10] Rao J,Wu N,Qu X,et al.The role of serum inammation-based factors in Anti-VEGF treatment for macular edema secondary to retinal vein occlusion and its subtypes[J].Ophthalmic Res,2020,64(2):171-173. |
|
|
|
2023, Vol. 29 
